Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and ou
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 StemGenex® , ... in the US aimed at improving the lives of ... clinical study for Parkinson’s disease. StemGenex believes that ... cell therapy are paramount when providing care to patients ... makes stem cell therapy accessible to the millions of ...
(Date:7/23/2014)... 2014 - Valentis ... Trendlines Agtech , announced it has signed an ... leading agricultural thermoplastics applications companies. ... combines nanocrystalline cellulose (NCC), a biodegradable, transparent material ... to produce highly improved polymeric films. Used as ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced that the underwriters of its common stock ... an additional 420,000 shares of common stock at ... less underwriting discounts and commissions, in connection with ... shares of common stock, bringing the expected net ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... Calif., Nov. 7 InterMune, Inc.,(Nasdaq: ITMN ) ... and President of InterMune, will present at Deutsche,Bank,s 2008 ... p.m. EST., To access a live audio webcast ... on to the investor relations page of InterMune,s,corporate website ...
... NeoGenomics, Inc.,(OTC Bulletin Board: NGNM) announced today ... present at the Rodman & Renshaw,10th Annual Healthcare ... New York Palace Hotel in New York City. ... public life sciences and biotech companies.,Gasparini and other ...
... Inc. (OTC,Bulletin Board: AIMM) today reported a net loss of ... three months ended September 30, 2008,compared with a net loss ... the three months ended September 30, 2007. For the nine ... $0.01 per share,basic and diluted, compared with net loss of ...
Cached Biology Technology:NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 3
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... , July 23, 2014   MedNet Solutions ... in clinical study management systems, is pleased to ... proven life sciences industry executive with over 25 ... Officer (COO).  Clareece will be responsible for MedNet,s ... operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... DNA has the nasty habit of getting tangled and ... function and learn how to disentangle them (e.g. useful ... International School for Advanced Studies (SISSA) in Trieste and ... they simulate these knots and their dynamics. In their ... Matter , Micheletti together with Marco Di Stefano, first ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3MedNet Appoints Clareece West As Chief Operating Officer 2
... Scott & White Healthcare in Temple, Texas, found that a new ... is unique in that it works both by stopping the cancer ... the immune system to destroy breast cancer cells and keeps them ... work in both ways, while all other treatments work in one ...
... , , ... Cotecna,Inspection SA, Philippines received accreditation from the Committee for,Accreditation ... break bulk,surveyor for cargo entering the Philippines. Cotecna is ... by the Philippine government under,their Administrative Order (AO) 243-A ...
... to drape those huge fake spider webs over doorways and ... long-standing mystery about real spider webs: It is the secret ... a new generation of biobased adhesives and glues "green" ... uses. A report on the study was published in ACS, ...
Cached Biology News:Scott & White Healthcare researcher finds success with new anti-cancer drug 2Cotecna Philippines Accredited as Bulk and Break Bulk Surveyor 2
... an 18 amino acid synthetic peptide whose sequences are derived from ... to carboxy terminus): S(21) - S - M - P - ... - A - I - D - K - K - ... This peptide may be used for neutralization and control experiments with ...
... System, Basic Package Superior Protein Detection ... The ProXPRESS 2D Proteomic Imaging System is ... both proteomic and general life science research ... the use of all dyes in the ...
... peptide microarrays designed for quantitative assays ... and built on the flexible and ... of customer specified sequences can be ... provide assistance with custom sequence design. ...
... extended-length microarrays are custom designed to meet ... are available: 8,455 features per array (2 ... features per array (1 array/slide). ... length - This extended length delivers ...
Biology Products: